Literature DB >> 24867078

WIN55,212-2 impairs non-associative recognition and spatial memory in rats via CB1 receptor stimulation.

A Galanopoulos1, A Polissidis1, G Georgiadou2, Z Papadopoulou-Daifoti3, G G Nomikos4, N Pitsikas2, K Antoniou5.   

Abstract

Endogenous and exogenous cannabinoids modulate learning and memory primarily via the cannabinoid type 1 receptor (CB1R). A variety of experimental procedures has focused on the role of CB1R in various aspects of learning and memory processes. However, the picture still remains unclear as there is a lack of information on the effects of relatively low doses of CB1R agonists in relation to their effects on locomotion. The present study sought to investigate CB1R activation, using a range of relatively low doses of the CB1R agonist WIN55,212-2, on multiple aspects of learning and memory in rats. For this purpose, non-associative learning was examined using the habituation of locomotion paradigm, recognition memory was evaluated with the novel object recognition task, and the radial water maze test was selected to assess rats' spatial memory. The ability of the CB1R antagonist, SR141716A, to counteract WIN55,212-2-induced behavioral effects was also tested. WIN55,212-2 (0.3, but not 0.03 or 0.1mg/kg) disrupted non-associative learning, different aspects of short- and long-term recognition memory (storage and retrieval) and retention of spatial memory. The 0.3mg/kg dose of WIN55,212-2 also decreased ambulatory, but not vertical (rearing), activity in non-habituated rats. These effects appeared to be CB1R dependent since pretreatment with SR141716A (0.03 mg/kg) prevented the WIN55,212-2-induced behavioral effects. The present findings further support and extend the complex impact of exogenous cannabinoids on learning and memory in relation to their effects on locomotion.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Behavioral habituation; Rat; Recognition memory; Spatial memory; WIN55,212-2

Mesh:

Substances:

Year:  2014        PMID: 24867078     DOI: 10.1016/j.pbb.2014.05.014

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  4 in total

1.  Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease.

Authors:  Jenny Ceccarini; Cindy Casteels; Rawaha Ahmad; Melissa Crabbé; Laura Van de Vliet; Heleen Vanhaute; Mathieu Vandenbulcke; Wim Vandenberghe; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-24       Impact factor: 9.236

2.  Cannabinoid Modulation of Memory Consolidation in Rats: Beyond the Role of Cannabinoid Receptor Subtype 1.

Authors:  Patrizia Ratano; Maura Palmery; Viviana Trezza; Patrizia Campolongo
Journal:  Front Pharmacol       Date:  2017-04-12       Impact factor: 5.810

3.  CB1 Activity Drives the Selection of Navigational Strategies: A Behavioral and c-Fos Immunoreactivity Study.

Authors:  Daniela Laricchiuta; Francesca Balsamo; Carlo Fabrizio; Anna Panuccio; Andrea Termine; Laura Petrosini
Journal:  Int J Mol Sci       Date:  2020-02-06       Impact factor: 5.923

4.  Valeriana jatamansi Jones ex Roxb. Against Post-Traumatic Stress Disorder, Network Pharmacological Analysis, and In Vivo Evaluation.

Authors:  Xue Yang; Jian-You Guo; Ya-Ni Jiang; Meng-Meng Liu; Qiu-Yu Li; Jia-Yuan Li; Xiao-Jia Wei; Guo-Hui Wan; Jin-Li Shi
Journal:  Front Pharmacol       Date:  2021-12-07       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.